Keith Davis, MD
Obstetrics & Gynecology · Fort Wayne, INNPI 1235129859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 144 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $942 and has fallen 68.1% since, to $300 in 2025.
Across 144 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$717
- Medical Device Business Services, Inc.$206
- Therapeuticsmd, Inc.$192
- Novo Nordisk$176
- Hologic Sales And Service, LLC$172
- Johnson & Johnson$154
- plus $2K from 28 others
Across 38 payments — averaging $3952.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$150K
What the payments were for
- Food & beverage$3,14699%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $717 |
| Medical Device Business Services, Inc. | 2 | $206 |
| Therapeuticsmd, Inc. | 5 | $192 |
| Novo Nordisk | 11 | $176 |
| Hologic Sales And Service, LLC | 4 | $172 |
| Johnson & Johnson | 5 | $154 |
| Lupin Inc. | 7 | $152 |
| Astellas Pharma US Inc | 7 | $149 |
| Myovant Sciences Inc. | 4 | $144 |
| Exeltis, USA Inc. | 7 | $103 |
| Davol Inc. | 2 | $91 |
| Organon | 6 | $88 |
| Pfizer | 10 | $84 |
| Daiichi Sankyo Inc. | 3 | $66 |
| Amgen | 4 | $60 |
| BD | 1 | $55 |
| Mayne Pharma Commercial LLC | 6 | $54 |
| Bayer | 4 | $54 |
| Aspira Women's Health Inc | 1 | $50 |
| Merck | 3 | $41 |
| Avion Pharmaceuticals | 3 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Medtronic | 1 | $36 |
| Baxter Healthcare | 1 | $32 |
| Millicent US Inc | 2 | $32 |
| Coopersurgical, Inc. | 2 | $30 |
| Axonics, Inc. | 1 | $28 |
| Biogen | 1 | $28 |
| AMAG Pharmaceuticals, Inc. | 2 | $27 |
| Dysis Medical, Inc. | 1 | $16 |
| Evofem Biosciences, Inc. | 1 | $15 |
| Channel Medsystems, Inc. | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Duchesnay USA Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,173 in reported general payments places this provider in the 80th percentile of 743 obstetrics & gynecology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 24 | $20,348 |
| PremarinEstrogens, Conjugated | 14 | $6,899 |
| Estradiol | 135 | $5,752 |
| OsphenaOspemifene | 15 | $4,952 |
| Estradiol-Norethindrone AcetatEstradiol/Norethindrone Acet | 15 | $2,276 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 30 | $808 |
| Raloxifene Hcl | 17 | $755 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $556 |
| Clobetasol Propionate | 20 | $521 |
| ProgesteroneProgesterone, Micronized | 13 | $391 |
| ValacyclovirValacyclovir Hcl | 14 | $313 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $305 |
| Medroxyprogesterone Acetate | 20 | $139 |
| Fluconazole | 13 | $109 |
| Alendronate Sodium | 22 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $149 | $20,34824 claims |
| PfizerPremarin | $84 | $6,89914 claims |
| Duchesnay USA IncorporatedOsphena | $12 | $4,95215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 743 obstetrics & gynecology providers in Indiana.
Other obstetrics & gynecology in Fort Wayne
- Ashley ScottFort Wayne$124K
- Francis EsguerraFort Wayne$11K
- Steven TannerFort Wayne$8K
- Regina Adair-BlackwellFort Wayne$6K
- Candace WestgateIndianapolis$123K
- Keith RamseyLake Station$116K
- Stefanie FloraCarmel$106K
- Lori DavidsonGreenwood$54K
- Julius Ellisla Porte$53K
- Emmary ButlerWinchester$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.